Gossamer Bio (GOSS) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Gossamer Bio (GOSS) over the past year, losing 47.5% versus a loss of 95.6%. Over five years, VTVT leads with a -71.1% price change compared with -98.7% for GOSS. Gossamer Bio is the larger company by market cap ($65.6 million vs $62.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | VTVT |
|---|---|---|
| Share price | $10.72 | $15.51 |
| Market cap | $65.57M | $62.22M |
| 1-day change | -4.54% | -5.20% |
| YTD return | -95.68% | -61.22% |
| 1-year return | -95.62% | -47.53% |
| 5-year return | -98.74% | -71.06% |
| EPS (TTM) | $-42.41 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $48.47M | $0 |
| Revenue growth (YoY) | -57.74% | -100.00% |
| Net income (latest FY) | $-170.37M | $-26.97M |
| Operating margin | -352.23% | — |
| Net margin | -351.49% | — |
| 52-week high | $309.60 | $44.00 |
| 52-week low | $8.29 | $15.47 |
| Distance from 52-week high | -96.54% | -64.75% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +669.40% | +261.06% |
| Average volume | 243.40K | 33.07K |
| Shares outstanding | 6.12M | 4.01M |
| Employees | 161 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed GOSS by 48.1 percentage points over the past year.
- Gossamer Bio grew revenue faster in its latest fiscal year (-57.74% vs -100.00%).
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
GOSS vs VTVT FAQ
Which is bigger, Gossamer Bio or vTv Therapeutics?
Gossamer Bio (GOSS) is larger, with a market capitalization of $65.57M compared with $62.22M for vTv Therapeutics (VTVT).
Which stock has performed better over the past year, GOSS or VTVT?
VTVT returned -47.53% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.